Latest Biotech News

Researchers from Boston Children’s Hospital and collaborators have developed an accelerated method to generate vascular organoids from human induced pluripotent stem cells (iPSCs) by...

Multiomics approaches integrating genomics, transcriptomics, and proteomics are increasingly central to life sciences. Ultima Genomics and partners like Olink Proteomics have collaborated to...

Engineers at the University of California San Diego have developed an evaporative cooling technology using fiber membranes with controlled porosity to passively dissipate heat from electronics....

Immunai has partnered with the Parker Institute for Cancer Immunotherapy to generate a large-scale, clinically annotated single-cell gene expression dataset from over 1,000 cancer patients...

Clinical trials and real-world data increasingly harness artificial intelligence and digital biomarkers to refine psychiatric treatment strategies. AI tools offer psychiatrists improved...

The FDA approved pembrolizumab for resectable locally advanced head and neck cancer with PD-L1 expression, based on data from the KEYNOTE-689 phase 3 trial showing improved event-free survival and...

Johnson and Johnson reported a 100% objective response rate in relapsed/refractory large B-cell lymphoma patients with one prior therapy using its dual CD19/CD20-targeting CAR-T. The therapy...

After discontinuing its only clinical-stage candidate, ADC Therapeutics announced closure of its UK R&D facility and a 30% staff reduction. Several early programs were halted to focus resources on...

The FDA has approved pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, marking the first checkpoint inhibitor approval in the...

Johnson and Johnson released encouraging phase 1b data for their dual-targeting CD19/CD20 CAR-T therapy in relapsed or refractory large B-cell lymphoma patients. The objective response rate was...

Insmed mailed a $750 million follow-on public equity offering following positive clinical data in hypertension. The financing round highlights growing investor confidence fueled by clinical...

Former CEO Anne Wojcicki’s nonprofit, the TTAM Research Institute, won a second auction to acquire 23andMe’s assets for $305 million, surpassing Regeneron’s prior bid. Agreement includes...

University of Michigan researchers conducted first quantum-mechanical simulations of quasicrystals, showing that these non-repeating atomic structures can be energetically stable. Employing...

Researchers reported a novel approach to generate functional vascular organoids by simultaneous activation of endothelial and mural lineage transcription factors ETV2 and NKX3.1. This method...

Two studies highlight advances in Parkinson’s research: one identifies perivascular fluid diffusivity as an early clinical progression biomarker using advanced MRI, enabling prognosis prior to...

The integration of proteomics with DNA sequencing technologies is accelerating multiomics approaches in biological research. Collaborations between Ultima Genomics and Olink Proteomics, as well as...

Notable FDA news includes approval of Moderna’s RSV vaccine expansion to at-risk younger adults and Medtronic’s clearance of a miniature defibrillation lead for pediatric use. Additionally,...

Innovations in artificial intelligence are reshaping scientific communication and drug discovery. AI-generated podcasts are effectively summarizing complex cardiovascular nursing research, gaining...

The FDA approved pembrolizumab for patients with resectable locally advanced head and neck squamous cell carcinoma expressing PD-L1, marking the first checkpoint inhibitor approval in this...

Anne Wojcicki’s nonprofit TTAM Research Institute secured 23andMe’s assets in a $305 million deal, outbidding Regeneron and committing to stringent privacy protections and continued data use for...